Mirador Therapeutics has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a potentially long-acting, sweeping anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation. The agreement expands Mirador’s precision immunology portfolio into inflammatory vascular disease. Kira will receive $12 million upon signing. The… Read More
UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 ($2.84) billion, including a record £2.05 ($2.76) billion in venture capital, according to new figures from the BioIndustry Association (BIA). The quarter was dominated by Isomorphic Labs’ landmark… Read More
As the world celebrates International Moon Day (20 July), Switzerland is championing the opportunities space exploration opens for life sciences. Leading international players including Starlab Space and Axiom Space have selected Switzerland as their European hub for the next generation of commercial orbital laboratories, supporting R&D in… Read More
DNA Script has announced a distribution agreement with Imperial Life Sciences (ILS) to expand access to the company’s DNA synthesis platform. The partnership will mean DNA Script’s SYNTAX platform will now be available in India. Under the agreement, ILS will distribute DNA Script’s SYNTAX platform throughout the country,… Read More
Evonik has announced a partnership with global antibody expression specialist evitria as it looks to accelerate its early biologics development. The collaboration is set to advance a transient protein expression kit based on CHO cells for biopharmaceutical research and development. Evonik says the kit is designed to enable… Read More
With the upcoming change of Prime Minister, the UK’s life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines. At a UK BioIndustry Association (BIA) industry roundtable with Dr Zubir Ahmed MP, the life sciences and… Read More
UK biotech Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion. The companies say the acquisition advances antibody-drug conjugate (ADC) innovation by bringing together the strengths of Novartis in oncology with Myricx Bio’s two lead ADC assets and next-generation first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform, having potential… Read More
BioCryst Pharmaceuticals has announced plans to discontinue its internal discovery programmes and close its Discovery Center of Excellence facility in Birmingham, Alabama by the end of 2026. The company says the moves are part of an ongoing strategic evolution to strengthen its rare disease pipeline. … Read More
A pan-European network has been established by iiCON: the Infection Innovation Consortium to help harmonise Europe’s response to infectious disease threats. iiCON secured funding from COST (European Cooperation in Science and Technology) to establish a pan-European COST Action network with over 70 collaborators from 21 countries and international… Read More
Anthropic has launched Claude Science, an app that it says integrates the tools and packages that researchers most commonly use, produces auditable artifacts, and provides flexible access to computing resources. At the launch event, the company also announced that it will be using the product to pursue… Read More
As DDW launches its new event series Drug Discovery Innovators & Investors, Lu Rahman looks at the challenges and opportunities that exist for both drug… Read More
Nxera Pharma has received $10 million after a fourth R&D milestone was met in the company’s collaboration with AbbVie. Nxera and AbbVie entered a multi-target collaboration in 2022 to leverage Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease. The fourth… Read More
Hansa Biopharma has closed a €115 million licensing transaction with SERB Pharmaceuticals for its kidney transplant drug in Europe and MENA. Idefirix is a first-in-class treatment that specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six hours. It is conditionally authorised by… Read More
Biopharmaceutical company Ipsen has agreed a deal to acquire Kartos Therapeutics, expanding its haemato-oncology late-stage pipeline. Ipsen will pay $450 million upfront as per the terms of the agreement, with Kartos Therapeutics shareholders eligible to receive payments of up to $1.3 million subject to regulatory approval milestones and sales-based milestones. … Read More
Drug Discovery World (DDW) is launching new series of events aimed at connecting innovation with investment in early-stage drug discovery. The Drug Discovery Innovators and Investors three-part series will comprise a digital forum (30 September 2026), and two in-person events (London, UK, 4 November 2026,… Read More
Merck and Bio-Techne have agreed that Merck will acquire Bio-Techne for $73 per share, representing a total enterprise value of approximately $11.3 billion. “This transaction is an important milestone towards delivering on our mid- to long-term strategic agenda. Bio-Techne is an outstanding fit that directly supports our… Read More
